Uli C. Broedl

The role of machine learning in clinical research: transforming the future of evidence generation

Correction to: The role of machine learning in clinical research: transforming the future of evidence generation

The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus

Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME ^® trial

Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes

Acute Pharmacodynamic Effects of Empagliflozin With and Without Diuretic Agents in Patients With Type 2 Diabetes Mellitus

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial